Nanodiagnostics to Face SARS-CoV-2 and Future Pandemics: From an Idea to the Market and Beyond.

Autor:	Rosati G; Institut Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain., Idili A; Institut Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain., Parolo C; Institut Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain., Fuentes-Chust C; Institut Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain., Calucho E; Institut Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain., Hu L; Institut Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain., Castro E Silva CC; Institut Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain.; MackGraphe-Mackenzie Institute for Research in Graphene and Nanotechnologies, Mackenzie Presbyterian University, Consolação street 930, 01302-907 São Paulo, Brazil., Rivas L; Institut Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain., Nguyen EP; Institut Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain., Bergua JF; Institut Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain., Alvárez-Diduk R; Institut Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain., Muñoz J; Institut Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain.; ISGlobal-Barcelona Institute for Global Health, Carrer del Rosselló, 132, 08036 Barcelona, Spain., Junot C; Université Paris-Saclay, CEA, INRAE Departement Médicaments et Technologies pour la Santé SPI, 91191 Gif-sur-Yvette cedex, France., Penon O; Asphalion, Carrer de Tarragona 151-157, 08014 Barcelona, Spain., Monferrer D; Asphalion, Carrer de Tarragona 151-157, 08014 Barcelona, Spain., Delamarche E; IBM Research-Zurich, 8803 Rüschlikon, Switzerland., Merkoçi A; Institut Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	ACS nano [ACS Nano] 2021 Nov 23; Vol. 15 (11), pp. 17137-17149. Date of Electronic Publication: 2021 Oct 27.
DOI:	10.1021/acsnano.1c06839
Abstrakt:	The COVID-19 pandemic made clear how our society requires quickly available tools to address emerging healthcare issues. Diagnostic assays and devices are used every day to screen for COVID-19 positive patients, with the aim to decide the appropriate treatment and containment measures. In this context, we would have expected to see the use of the most recent diagnostic technologies worldwide, including the advanced ones such as nano-biosensors capable to provide faster, more sensitive, cheaper, and high-throughput results than the standard polymerase chain reaction and lateral flow assays. Here we discuss why that has not been the case and why all the exciting diagnostic strategies published on a daily basis in peer-reviewed journals are not yet successful in reaching the market and being implemented in the clinical practice.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu